These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 23030677)

  • 1. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA's Approach to Regulating Biosimilars.
    Lemery SJ; Ricci MS; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2017 Apr; 23(8):1882-1885. PubMed ID: 28034906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on the Current State of the Biosimilar Regulatory Pathway in the United States.
    Dougherty MK; Zineh I; Christl L
    Clin Pharmacol Ther; 2018 Jan; 103(1):36-38. PubMed ID: 29152721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
    Hung A; Vu Q; Mostovoy L
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interchangeability Of Biological Drug Products-FDA Draft Guidance.
    Endrenyi L; Markus R
    J Biopharm Stat; 2019; 29(6):1003-1010. PubMed ID: 31023141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars: The US Regulatory Framework.
    Christl LA; Woodcock J; Kozlowski S
    Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: Here and Now.
    Lemery SJ; Esteva FJ; Weise M
    Am Soc Clin Oncol Educ Book; 2016; 35():e151-7. PubMed ID: 27249717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sowing confusion in the field: the interchangeable use of biosimilar terminology.
    McKinley L; Kelton JM; Popovian R
    Curr Med Res Opin; 2019 Apr; 35(4):619-621. PubMed ID: 30556742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are biosimilars patentable?
    Rolfe D; Parker J; Morgan M
    Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology.
    Nikolov NP; Shapiro MA
    Nat Rev Rheumatol; 2017 Feb; 13(2):123-128. PubMed ID: 28053335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study.
    He K; Chen H; Gwise T; Casak S; Lemery S; Keegan P; Pazdur R; Sridhara R
    Clin Cancer Res; 2016 Nov; 22(21):5167-5170. PubMed ID: 27582485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial development for biosimilars.
    Alten R; Cronstein BN
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
    Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
    JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 38.